How to Treat Asthma in an Adult
All adults with asthma should receive inhaled corticosteroid (ICS)-containing treatment, and short-acting beta2-agonist (SABA)-only treatment is strongly contraindicated. 1, 2
Preferred Treatment Approach: Track 1 (Anti-Inflammatory Reliever Strategy)
The most current evidence supports using low-dose ICS-formoterol as both maintenance and reliever therapy across all severity levels 1, 2. This approach reduces severe exacerbations by more than 60% compared to SABA-only treatment 2.
Stepwise Treatment Algorithm
Step 1 (Mild Intermittent):
- As-needed low-dose ICS-formoterol only (budesonide-formoterol 160/4.5 μg)
- Use when symptoms occur less than twice monthly, no nocturnal symptoms, FEV1 >80% predicted 3
Step 2 (Mild Persistent):
- Continue as-needed low-dose ICS-formoterol only
- This significantly reduces moderate-to-severe exacerbations versus SABA monotherapy 3, 2
Step 3 (Moderate Persistent):
- Daily maintenance low-dose ICS-formoterol PLUS as-needed ICS-formoterol (MART regimen)
- Adding long-acting beta2-agonist (LABA) to ICS consistently improves symptoms better than doubling ICS dose 4, 5
Step 4 (Moderate-to-Severe):
- Increase to medium-dose ICS-formoterol maintenance plus as-needed ICS-formoterol
- Consider adding long-acting muscarinic antagonist (LAMA) as triple therapy 4, 3
Step 5 (Severe Uncontrolled):
- High-dose ICS-formoterol maintenance plus as-needed ICS-formoterol
- Add biologic therapy for type 2 inflammation (elevated eosinophils ≥150/μl, FeNO ≥35 ppb, or elevated IgE) 3
- Consider low-dose azithromycin (250-500 mg three times weekly) for persistent symptoms 3
- Low-dose oral corticosteroids (≤7.5 mg/day prednisone equivalent) only as last resort 3
Alternative Treatment Approach: Track 2
If ICS-formoterol is unavailable, use separate inhalers:
- Daily ICS (low-dose at Step 2, medium-dose at Step 3, high-dose at Steps 4-5)
- Add separate LABA at Step 3 and above 4
- As-needed SABA for symptom relief (though this carries higher exacerbation risk than Track 1) 2
Critical Monitoring Requirements
Assess every 2-4 weeks initially, then every 1-3 months:
- Symptom control (daytime symptoms, nighttime awakenings, activity limitation, reliever use)
- Lung function (FEV1, FEV1/FVC ratio, bronchodilator reversibility)
- Inhaler technique and adherence at every visit 4, 3
- Type 2 biomarkers: peripheral blood eosinophils, FeNO, total IgE 3
- Exacerbation frequency and oral corticosteroid courses 4
Common Pitfalls to Avoid
Never prescribe SABA monotherapy - this increases severe exacerbations and asthma-related deaths 1, 2. Even patients with infrequent symptoms need ICS-containing treatment.
Do not overuse SABA - more than one canister monthly indicates poor control and increased death risk 3. This signals need to step up ICS-containing therapy.
Avoid high-dose ICS without adding LABA first - combination therapy achieves better outcomes than quadrupling ICS dose, with fewer systemic corticosteroid effects 4, 5.
Do not use LABA as monotherapy - patients must continue ICS when taking LABA, as LABA-only treatment increases severe exacerbations 4.
Beware of incorrect inhaler technique - this is the most common cause of treatment failure. Verify technique at every visit before escalating therapy 4, 3.
Severe Asthma Management
Define severe asthma as uncontrolled despite 3+ months of medium-to-high-dose ICS-LABA, after addressing comorbidities and environmental triggers 3.
Before adding biologics, confirm:
- Correct diagnosis (consider bronchial provocation testing if FEV1 ≥70% predicted) 3
- Optimal inhaler technique and adherence
- Treatment of comorbidities (rhinosinusitis, GERD, obesity, anxiety/depression) 4, 3
- Avoidance of triggers (smoking, occupational exposures, allergens)
Biologic selection for type 2 severe asthma:
- Anti-IgE (omalizumab): elevated total IgE with allergic sensitization
- Anti-IL-5/IL-5Rα (mepolizumab, reslizumab, benralizumab): elevated eosinophils ≥150-300/μl
- Anti-IL-4Rα (dupilumab): elevated eosinophils and/or FeNO, particularly with nasal polyps 3
All biologics reduce exacerbations and allow oral corticosteroid reduction in appropriate phenotypes 3.
Essential Non-Pharmacologic Management
- Written asthma action plan for all patients 6, 2
- Trigger avoidance (allergens, irritants, NSAIDs if aspirin-sensitive, beta-blockers) 4
- Smoking cessation (active and passive exposure)
- Annual influenza vaccination
- Consider allergen immunotherapy for HDM-sensitized patients with FEV1 >70% on low-to-medium-dose ICS 3
When to Refer to Specialist
Refer immediately if:
- Uncontrolled on Step 4 treatment despite correct technique and adherence 3
- Frequent exacerbations (≥2 oral corticosteroid courses yearly)
- History of near-fatal asthma or ICU admission
- Diagnostic uncertainty (elderly, smokers, atypical features) 7
- Consideration for biologic therapy or bronchial thermoplasty 3
The evidence strongly favors ICS-formoterol as anti-inflammatory reliever therapy over traditional SABA-based regimens, representing the most significant paradigm shift in asthma management in recent years 1, 2.